Granules India (NSE:GRANULES) ROCE % : 23.78% (As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Granules India ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Granules India's annualized ROCE % for the quarter that ended in Mar. 2024 was 23.78%.

Granules India ROCE % Historical Data

The historical data trend for Granules India's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Granules India ROCE % Chart

Granules India Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

21.39

29.70

21.06

24.93

20.00

Granules India Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															23.65	11.38	20.27	24.88	23.78

Granules India ROCE % Calculation

Granules India's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	6530.5	/	( ( (49045.64 - 18135.01)	+	(55209.82 - 20822.93) )	/ 2 )
	=	6530.5	/	( (30910.63	+	34386.89)	/ 2 )
	=	6530.5	/	32648.76
	=	20.00 %

Granules India's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	8175.92	/	( ( (0 - 0)	+	(55209.82 - 20822.93) )	/ 1 )
	=	8175.92	/	( ( 0	+	34386.89 )	/ 1 )
	=	8175.92	/	34386.89
	=	23.78 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Granules India (NSE:GRANULES) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Granules India ROCE % Related Terms

Thank you for viewing the detailed overview of Granules India's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Granules India (NSE:GRANULES) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Granules India Ltd (NSE:GRANULES) » Definitions » ROCE %

Traded in Other Exchanges

532482:India

Address

3rd Block, My Home Hub, 2nd Floor, Madhapur, Hyderabad, TG, IND, 500 081

Website

https://www.granulesindia.com

Granules India Ltd is an India-based pharmaceutical company. The company manufactures active pharmaceutical ingredients, pharmaceutical formulation intermediates and finished dosages. Its business is organized into three areas; the Core business which comprises core molecules such as Paracetamol, Ibuprofen, Metformin, Guaifenesin, and Methocarbamol; the Emerging business that focuses on manufacturing APIs and the US Generics. It has one segment Pharmaceutical products including ingredients and intermediaries. Its primary geographic markets are North America, Latin America, Europe, India, and Rest of World.

Granules India (NSE:GRANULES) Headlines

No Headlines